Publicacions en col·laboració amb investigadors/es de Universidad de Navarra (87)

2023

  1. Epiphyseal distraction prior to resection in paediatric bone sarcomas : four decades of experience

    The bone & joint journal, Vol. 105-B, Núm. 1, pp. 11-16

  2. Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies

    Biomedicines, Vol. 11, Núm. 2

2022

  1. A Quantitative Digital Analysis of Tissue Immune Components Reveals an Immunosuppressive and Anergic Immune Response with Relevant Prognostic Significance in Glioblastoma

    Biomedicines, Vol. 10, Núm. 7

  2. A Reassessment of the Barrier Effect of the Physis against Metaphyseal Osteosarcoma: A Comprehensive Pathological Study with Its Radiological and Clinical Follow-Up Correlations

    Diagnostics, Vol. 12, Núm. 2

  3. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  4. Clinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spain

    Cancer Epidemiology, Vol. 76

  5. Granuloma annulare subtypes: sonographic features and clinicopathological correlation

    Journal of Ultrasound, Vol. 25, Núm. 2, pp. 289-295

  6. Leiomyosarcoma of the nasal fossa. A case report

    Revista Espanola de Patologia, Vol. 55, Núm. 3, pp. 192-196

  7. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells

    International Journal of Oncology, Vol. 58, Núm. 3, pp. 312-330

  2. Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

    Therapeutic Advances in Medical Oncology, Vol. 13

  3. Minimally invasive tumor bed implant (MITBI) and peri-operative high-dose-rate brachytherapy (PHDRBT) for accelerated minimal breast irradiation (AMBI) or anticipated boost (A-PHDRBT-boost) in breast-conserving surgery for ductal carcinoma in situ

    Journal of Contemporary Brachytherapy, Vol. 12, Núm. 6, pp. 521-532

  4. Silencing of histone deacetylase 6 decreases cellular malignancy and contributes to primary cilium restoration, epithelial-to-mesenchymal transition reversion, and autophagy inhibition in glioblastoma cell lines

    Biology, Vol. 10, Núm. 6

2020

  1. Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence

    Modern Pathology, Vol. 33, Núm. 12, pp. 2507-2519

  2. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation

    Neuromuscular Disorders, Vol. 30, Núm. 1, pp. 67-69

  3. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice

    Clinical Cancer Research, Vol. 26, Núm. 16, pp. 4186-4197

  4. The synergistic effect of DZ-NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells

    International Journal of Oncology, Vol. 56, Núm. 1, pp. 283-300

2019

  1. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Thorax, Vol. 74, Núm. 4, pp. 371-379

  2. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience

    PLoS ONE, Vol. 14, Núm. 6

  3. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476